氧化铁纳米颗粒通过与紫杉醇协同捆绑,通过自噬途径诱导铁死亡。

Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel.

机构信息

Guangxi Clinical Medical Research Center for Neurological Diseases, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.

出版信息

Mol Med Rep. 2023 Oct;28(4). doi: 10.3892/mmr.2023.13085. Epub 2023 Sep 8.

Abstract

In recent years, inhibiting tumor cell activity by triggering cell ferroptosis has become a research hotspot. The development of generic targeted nanotherapeutics might bring new ideas for non‑invasive applications. Currently, the potential mechanism underlying the universal application of paclitaxel (PTX)‑loaded iron oxide nanoparticles (IONP@PTX) to different types of tumors is unclear. The present study aimed to prepare IONP@PTX for targeted cancer therapy and further explore the potential mechanisms underlying the inhibitory effects of this material on the NCI‑H446 human small cell lung cancer and brain M059K malignant glioblastoma cell lines. First, a CCK‑8 assay was performed to determine cell viability, and then the combination index for evaluating drug combination interaction effect was evaluated. Intracellular reactive oxygen species (ROS) and lipid peroxidation levels were monitored using a DCFH‑DA fluorescent probe and a C11‑BODIPY™ fluorescent probe, respectively. Furthermore, western blotting assay was performed to determine the expression of autophagy‑ and iron death‑related proteins. The experimental results showed that, compared with either IONP monotherapy, PTX monotherapy, or IONP + PTX, IONP@PTX exerted a synergistic effect on the viability of both cell types, with significantly increased total iron ion concentration, ROS levels and lipid peroxidation levels. IONP@PTX significantly increased the expression of autophagy‑related proteins Beclin 1 and histone deacetylase 6 (HDAC6) in both cell lines (P<0.05), increased the expression of light chain 3 (LC3)‑II/I in NCI‑H446 cells (P<0.05) and decreased that of sequestosome1 (p62) in M059K cells (P<0.05). Moreover, the addition of rapamycin enhanced the IONP@PTX‑induced the upregulation of Beclin 1, LC3‑II/I and HDAC6 and the downregulation of mTORC1 protein in both cell lines (P<0.05). Moreover, rapamycin enhanced the IONP@PTX‑induced downregulation of p62 protein in NCI‑H446 cells (P<0.05), suggesting that IONP@PTX induces ferroptosis, most likely through autophagy. Collectively, the present findings show that IONP works synergistically with PTX to induce ferroptosis via the autophagic pathway.

摘要

近年来,通过触发细胞铁死亡来抑制肿瘤细胞活性已成为研究热点。通用靶向纳米治疗药物的发展可能为非侵入性应用带来新的思路。目前,紫杉醇(PTX)负载氧化铁纳米粒子(IONP@PTX)应用于不同类型肿瘤的普遍作用机制尚不清楚。本研究旨在制备 IONP@PTX 进行靶向癌症治疗,并进一步探讨该材料对 NCI-H446 人小细胞肺癌和脑 M059K 恶性神经胶质瘤细胞系的抑制作用的潜在机制。首先,通过 CCK-8 测定法测定细胞活力,然后评估评估药物联合作用效果的联合指数。使用 DCFH-DA 荧光探针和 C11-BODIPY™荧光探针分别监测细胞内活性氧(ROS)和脂质过氧化水平。此外,通过 Western blot 测定法测定自噬和铁死亡相关蛋白的表达。实验结果表明,与 IONP 单药治疗、PTX 单药治疗或 IONP+PTX 相比,IONP@PTX 对两种细胞类型的活力均表现出协同作用,总铁离子浓度、ROS 水平和脂质过氧化水平显著升高。IONP@PTX 显著增加了两种细胞系中自噬相关蛋白 Beclin 1 和组蛋白去乙酰化酶 6(HDAC6)的表达(P<0.05),增加了 NCI-H446 细胞中 LC3-II/I 的表达(P<0.05),并降低了 M059K 细胞中 sequestosome1(p62)的表达(P<0.05)。此外,雷帕霉素的添加增强了 IONP@PTX 诱导的 Beclin 1、LC3-II/I 和 HDAC6 的上调以及 mTORC1 蛋白在两种细胞系中的下调(P<0.05)。此外,雷帕霉素增强了 IONP@PTX 诱导的 NCI-H446 细胞中 p62 蛋白的下调(P<0.05),表明 IONP@PTX 通过自噬诱导铁死亡。综上所述,本研究结果表明,IONP 与 PTX 协同作用通过自噬途径诱导铁死亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a43b/10510030/d534d388c5ca/mmr-28-04-13085-g00.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索